2005
Suicidal ideation among African-American non-injection drug users.
Havens J, Ompad D, Latkin C, Fuller C, Arria A, Vlahov D, Strathdee S. Suicidal ideation among African-American non-injection drug users. Ethnicity & Disease 2005, 15: 110-5. PMID: 15720057.Peer-Reviewed Original ResearchConceptsSuicidal ideationDrug usersDrug dependenceNon-injection drug usersCommunity-based cohortInterview-administered questionnaireMultiple logistic regressionDrug use historyUse of heroinAfrican American drug usersMedian agePsychiatric comorbidityDepressive symptomsMore drugsSuicidal thoughtsLogistic regressionIdeationAfrican AmericansUse historyParticipantsComorbiditiesCohortSymptomsYearsHeroin
1999
Direct Comparison of Time to AIDS and Infectious Disease Death Between HIV Seroconverter Injection Drug Users in Italy and the United States: Results From the ALIVE and ISS Studies
Pezzotti P, Galai N, Vlahov D, Rezza G, Lyles C, Astemborski J. Direct Comparison of Time to AIDS and Infectious Disease Death Between HIV Seroconverter Injection Drug Users in Italy and the United States: Results From the ALIVE and ISS Studies. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1999, 20: 275-282. PMID: 10077177, DOI: 10.1097/00042560-199903010-00010.Peer-Reviewed Original ResearchConceptsInjection drug usersDate of seroconversionYear of seroconversionMedian timeRelative hazardGroups of IDUsDrug usersInfectious diseasesCohort of IDUsFirst positive HIV testClinic-based cohortSimilar median timeHIV disease progressionProspective cohort studyPositive HIV testInjection drug useCommunity-based cohortHIV-positive individualsInfectious disease deathsTime of seroconversionDrug use characteristicsTerms of ageProportion of womenALIVE studyCohort study
1995
Instability of Delayed-type Hypersensitivity Skin Test Anergy in Human Immunodeficiency Virus Infection
Caiaffa W, Graham N, Galai N, Rizzo R, Nelson K, Vlahov D. Instability of Delayed-type Hypersensitivity Skin Test Anergy in Human Immunodeficiency Virus Infection. JAMA Internal Medicine 1995, 155: 2111-2117. PMID: 7575072, DOI: 10.1001/archinte.1995.00430190107015.Peer-Reviewed Original ResearchConceptsHIV-seropositive subjectsHIV-seronegative subjectsCD4 cell countSkin test resultsDrug usersCell countDTH anergyDTH positivityDelayed-type hypersensitivity (DTH) skin testDelayed-type hypersensitivity anergyHuman immunodeficiency virus (HIV) infectionDTH skin testingSkin test anergyImmunodeficiency virus infectionCommunity-based cohortHuman immunodeficiency virusHypersensitivity skin testsCandida albicans antigenAnergy testingSerial skinCD4 cellsHIV statusSingle testSkin testingImmunodeficiency virus
1992
Prevalence of Tuberculin Positivity and Skin Test Anergy in HIV-1—Seropositive and —Seronegative Intravenous Drug Users
Graham N, Nelson K, Solomon L, Bonds M, Rizzo R, Scavotto J, Astemborski J, Vlahov D. Prevalence of Tuberculin Positivity and Skin Test Anergy in HIV-1—Seropositive and —Seronegative Intravenous Drug Users. JAMA 1992, 267: 369-373. PMID: 1727959, DOI: 10.1001/jama.1992.03480030047035.Peer-Reviewed Original ResearchConceptsIntravenous drug usersHIV-1 seropositivesSkin test anergyHIV-1 seropositive groupSeronegative intravenous drug usersTuberculin positivityLymphocyte countPPD positivityHIV-1-seropositive intravenous drug usersPPD tuberculinDrug usersHuman immunodeficiency virus serostatusSeropositive intravenous drug usersHIV-1 seropositive patientsTuberculin skin test resultsHIV-1 seronegativeHIV-1 seronegativesPPD test resultsHIV-1 seropositivityDelayed-type hypersensitivityCommunity-based cohortSkin test resultsYears of agePositive test resultsInverse linear trend